Aadi Bioscience (AADI) Scheduled to Post Quarterly Earnings on Wednesday

Aadi Bioscience (NASDAQ:AADI) is scheduled to be issuing its quarterly earnings data before the market opens on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Aadi Bioscience (NASDAQ:AADI) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.02). Aadi Bioscience had a negative return on equity of 61.83% and a negative net margin of 288.72%. The firm had revenue of $5.35 million during the quarter, compared to analyst estimates of $6.41 million. On average, analysts expect Aadi Bioscience to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Aadi Bioscience Stock Up 1.1 %

Shares of Aadi Bioscience stock traded up $0.02 during mid-day trading on Tuesday, reaching $1.40. 38,199 shares of the stock traded hands, compared to its average volume of 288,040. The business has a 50-day moving average of $1.59 and a 200 day moving average of $1.83. The stock has a market capitalization of $34.25 million, a PE ratio of -0.55 and a beta of 0.69. Aadi Bioscience has a fifty-two week low of $1.28 and a fifty-two week high of $7.24.

Insider Buying and Selling

In related news, Chairman Neil Desai sold 31,348 shares of the stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1.45, for a total value of $45,454.60. Following the transaction, the chairman now directly owns 1,260,195 shares of the company’s stock, valued at approximately $1,827,282.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders sold 52,415 shares of company stock worth $76,151. Corporate insiders own 37.30% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “neutral” rating on shares of Aadi Bioscience in a report on Tuesday, May 14th.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.